Table 1.

Summary of patient characteristics by ON etiologies.

	Overall N = 160	SION N = 78	MS‐ON N = 41	NMOSD‐ON N = 15	MOGAD‐ON N = 26
Sex, female (present, n (%))	109 (68%)	50 (64%)	28 (68%)	14 (93%)	17 (65%)
Age in years (mean, SD)	37 (12)	39 (13)	33 (8)	43 (14)	36 (10)
Ethnicity (present, n (%))
White	109 (68%)	53 (68%)	33 (80%)	5 (33%)	18 (69%)
Latin	16 (10%)	9 (12%)	1 (2.4%)	3 (20%)	3 (12%)
Arab	11 (7%)	7 (9%)	0 (0%)	1 (7%)	3 (12%)
Asian	9 (6%)	7 (9.0%)	0 (0%)	0 (0%)	2 (8%)
Black	5 (3%)	0 (0%)	3 (7%)	2 (13%)	0 (0%)
HCVA at nadir in decimals (mean, SD)	0.35 (0.35)	0.39 (0.35)	0.50 (0.36)	0.09 (0.20)	0.16 (0.23)
Unilateral painful vision loss (present, n (%))	109 (68%)	58 (74%)	31 (76%)	8 (53%)	12 (46%)
Unilateral painless vision loss (present, n (%))	21 (13%)	10 (13%)	9 (22%)	0 (0%)	2 (8%)
Bilateral vision loss (present, n (%))	30 (19%)	10 (13%)	1 (2.4%)	7 (47%)	12 (46%)
Dyschromatopsia (present, n (%))	111 (69%)	59 (76%)	25 (61%)	11 (73%)	16 (62%)
RAPD (present, n (%))	108 (68%)	57 (73%)	26 (63%)	11 (73%)	14 (54%)
OCT abnormalities (present, n (%)) a	70 (44%)	36 (46%)	17 (41%)	6 (40%)	11 (42%)
MRI abnormalities (present, n (%)) a	128 (80%)	57 (73%)	32 (78%)	14 (93%)	25 (96%)
Biomarker (OCB, AQP4‐, MOG‐IgG) present (present, n (%))	81 (51%)	16 (21%)	28 (68%)	14 (93%)	26 (100%)

AQP4‐IgG, aquaporin‐4‐IgG; MOG‐IgG, myelin oligodendrocyte glycoprotein‐IgG; MOGAD, myelin oligodendrocyte glycoprotein antibody‐associated disease; MRI, magnetic resonance imaging; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; OCB, oligoclonal bands; OCT, optical coherence tomography; ON, optic neuritis; RAPD, relative afferent pupillary defect; SD, standard deviation; SION, single isolated optic neuritis.

^a According to abnormalities described in 2022 ICON definitions. ⁶